Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

Zhe Chen; Hong-yun Chen; Qing-bo Lang; Bai Li; Xiao-feng Zhai; Yu-yu Guo; Xiao-qiang Yue; Chang-quan Ling

doi:10.1007/s11655-012-1083-1

Your Location：

Home >

Browse articles >

Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

Updated：2021-08-27

- Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial
- Chinese Journal of Integrative Medicine Vol. 18, Issue 5, Pages: 339-344(2012)
- Affiliations：
  
  Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University,Shanghai,China
- Author bio：
- Funds：
  
  Supported by National Key Technology R&D Program for the 11th Five-Year Plan (No. 2006 BAI04A06);These authors contributed equally to this work
- DOI：10.1007/s11655-012-1083-1
  CLC：
- Published：2012，
  
  Published Online：2 May 2012，
Scan for full text
Chen, Z., Chen, Hy., Lang, Qb. et al. Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial., Chin. J. Integr. Med. 18, 339–344 (2012). https://doi.org/10.1007/s11655-012-1083-1

Zhe Chen, Hong-yun Chen, Qing-bo Lang, et al. Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial. [J]. Chinese Journal of Integrative Medicine 18(5):339-344(2012)
Chen, Z., Chen, Hy., Lang, Qb. et al. Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial., Chin. J. Integr. Med. 18, 339–344 (2012). https://doi.org/10.1007/s11655-012-1083-1 DOI：

Zhe Chen, Hong-yun Chen, Qing-bo Lang, et al. Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial. [J]. Chinese Journal of Integrative Medicine 18(5):339-344(2012) DOI： 10.1007/s11655-012-1083-1.

摘要

To investigate the therapeutic effects of Jiedu Granules (解毒颗粒)

a Chinese medicine (CM) compound

plus Cinobufacini Injection (华蟾素注射液)

which was extracted from skin of Bufo bufo gargarizans Cantor

to prevent the recurrence of hepatocellular carcinoma (HCC) after surgical resection. In this case-control trial

a total of 120 patients who stayed in Changhai Hospital were enrolled from December 2001 to December 2006. Sixty patients were treated with Jiedu Granules plus Cinobufacini Injection to prevent tumor recurrence after operation (CM group) and 60 patients were treated with transcatheter arterial chemoembolization (TACE) after operation (TACE group). Progression-free survival (PFS) and overall survival (OS) rates were determined to evaluate the therapeutic effects of post-operative management of patients with HCC. PFS in the CM group was 18.07 months [95% confidence interval (CI): 12.49–23.65] and the 1-

4- and 5-year PFS rates were 61%

39%

26%

22% and 12%

respectively. PFS in the TACE group was 8.03 months (95% CI: 6.63–9.44) and the 1-

4- and 5-year PFS rates were 34%

11%

2% and 0%

respectively. There was significant difference in survival rate between the two groups (P<0.01). The mean survival time (MST) of patients in the CM group was 49.53 months versus 39.90 months of the TACE group. The 1-

4- and 5-year survival rates were 90%

82%

80%

70% and 63%

respectively

in the CM group

and 79%

70%

60%

60% and 36%

respectively

in the TACE group. There was significant difference in survival time between the two groups (P=0.045). Jiedu Granules plus Cinobufacini Injection

a combination that is commonly used for post-operation management of HCC

can postpone tumor recurrence and metastasis

prolong the survival time and increase the survival rate of post-surgical patients with HCC. However

these findings need to be confirmed in a prospective

randomized controlled trial.

Abstract

To investigate the therapeutic effects of Jiedu Granules (解毒颗粒)

a Chinese medicine (CM) compound

plus Cinobufacini Injection (华蟾素注射液)

which was extracted from skin of Bufo bufo gargarizans Cantor

to prevent the recurrence of hepatocellular carcinoma (HCC) after surgical resection. In this case-control trial

4- and 5-year PFS rates were 61%

39%

26%

22% and 12%

respectively. PFS in the TACE group was 8.03 months (95% CI: 6.63–9.44) and the 1-

4- and 5-year PFS rates were 34%

11%

2% and 0%

4- and 5-year survival rates were 90%

82%

80%

70% and 63%

respectively

in the CM group

and 79%

70%

60%

60% and 36%

respectively

in the TACE group. There was significant difference in survival time between the two groups (P=0.045). Jiedu Granules plus Cinobufacini Injection

a combination that is commonly used for post-operation management of HCC

can postpone tumor recurrence and metastasis

prolong the survival time and increase the survival rate of post-surgical patients with HCC. However

these findings need to be confirmed in a prospective

randomized controlled trial.

关键词

hepatocellular carcinomatranscatheter arterial chemoembolizationrecurrencemetastasisChinese MedicineJiedu GranulesCinobufacini Injection

Keywords

hepatocellular carcinomatranscatheter arterial chemoembolizationrecurrencemetastasisChinese MedicineJiedu GranulesCinobufacini Injection

references

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535–1547.

Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440.

Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322–330.

Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181–200.

Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol 2002;3:593–603.

Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187–196.

Ling CQ. Effect and status of traditional Chinese medicine on tumor. Chin J Integr Tradit West Med (Chin) 2007;27:390–391.

Ling CQ. Problems in cancer treatment and major research of integrative medicine. J Chin Integr Med (Chin) 2003;1:168–170.

Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. J Chin Integr Med (Chin) 2003;1:163–164.

Han KQ, Gu W, Su YH, Huang XQ, Wang X, Ling CQ. Antitumor effects of bufalin on the orthotopic transplantation tumor model of hepatocellular carcinoma in mice. Chin J Exp Surg (Chin) 2004;21:1436–1438.

Su YH, Huang XQ, Zhang DZ, Zhang YY, Xie JM, Ling CQ. HPLC separation and determination of bufadienolide in Cinobufacini Injection. Chin Tradit Patent Med (Chin) 2003;25:24–27.

Su YH, Yin XC, Xie JM, Gao B, Ling CQ. Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines. Acad J Sec Milit Med Univ 2003;24:393–395.

Ma YJ, Ma YP. Cinobufacini Injection treatment of advanced primary liver cancer clinical observation. J Liaoning Univ Tradit Chin Med (Chin) 2010;12:123–124.

Zhou X, Yang JK, Zhu LQ, Gao F, Xie RF, Gu XJ. Meta analysis on Cinobufacini injection in hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J New Drugs Clin Remed (Chin) 2009;9:671–674.

Yang BH, Xia JL. Criteria for diagnosis and staging of primary liver cancer. Cancer Res Prev Treat (Chin) 2002;29:83.

National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 2.2008). National Comprehensive Cancer Network, Inc.

Liu PF, Liu RH, Xu H, Wu MC. Significance of preventive TACE in primary liver cancer after operation. Chin J Hepatobil Surg (Chin) 2005;11:81–82.

Tanaka K, Shimada H, Togo S, Takahashi T, Endo I, Sekido H, et al. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 1999;46:1083–1088.

Liu PF, Liu RH, Xu H, Wu MC. Significance of preventive TACE in primary cancer after operation. Chin J Hepatobil Surg (Chin) 2005;11(2):81–82.

Wu HP, Feng GS. Status quo and prospect of interventional therapy of liver cancer. J Clin Radiol (Chin) 2005;24:273–276.

An FQ, Matsuda M, Fujii H, Matsumoto Y. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 2000;126:153–160.

Xi T, Shen F, Wu MC. Effect of postoperative prophylactic transcatheter arterial chemoembolization on delaying recurrence in patients with hepatocellular carcinoma. Chin Tumor (Chin) 2005;14:161–163.

Miao CL, Yu QF, Liang HF. Clinical research of Cinobufacini Injection combined with chemotherapeutic in treating patients with advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2007;27:657–658.

Hao CL. Cinobufacini Injection in treatment cancer and its advance effects. China Pharmacist (Chin) 2007;10:704–706.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Sublingual Nodules: Diagnostic Markers of Metastatic Breast Cancer

Nodule and eminence on frenulum labii superioris: Diagnostic markers for metastatic colorectal cancer

Total saponin from root of Actinidia Valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells

Effects on the tumor specific growth factor and tumor necrosis factor α in rats’ precancerous lesion of primary hepatocellular carcinoma by direct moxibustion at Ganshu (BL 18) acupoint

Bear bile powder inhibits angiogenesis in vivo and in vitro

Related Author

No data

Related Institution

National Clinical Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital

Department of Medical Oncology, Tianjin Medical Universty General Hospital

Zhong-Shan-Men In-patient Department, Tianjin Medical University Cancer Institute and Hospital

National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital

Tianjin Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰